Applied Therapeutics, Inc.
APLT
$0.5143
$0.00020.04%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 136.64% | 155.77% | -95.44% | -101.98% | -103.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 136.64% | 155.77% | -95.44% | -101.98% | -103.12% |
| Cost of Revenue | -8.33% | -11.60% | -9.58% | -44.45% | -42.11% |
| Gross Profit | 9.21% | 12.96% | -9.96% | 37.11% | 33.18% |
| SG&A Expenses | 128.71% | 168.10% | 171.58% | 76.80% | 22.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.51% | 46.71% | 40.55% | 25.85% | 0.88% |
| Operating Income | -42.74% | -45.42% | -61.61% | -47.65% | -17.59% |
| Income Before Tax | 57.95% | 77.52% | 11.81% | -94.08% | -119.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 57.95% | 77.52% | 11.81% | -94.08% | -119.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.95% | 77.52% | 11.81% | -94.08% | -119.93% |
| EBIT | -42.74% | -45.42% | -61.61% | -47.65% | -17.59% |
| EBITDA | -42.74% | -45.42% | -61.61% | -47.66% | -17.59% |
| EPS Basic | 67.88% | 83.74% | 39.79% | -11.87% | -17.49% |
| Normalized Basic EPS | 67.87% | 83.75% | 39.78% | -11.78% | -17.43% |
| EPS Diluted | 70.51% | 75.47% | 28.55% | -23.33% | -29.59% |
| Normalized Diluted EPS | 67.90% | 83.68% | 39.69% | -11.87% | -17.52% |
| Average Basic Shares Outstanding | 23.01% | 42.40% | 65.79% | 89.89% | 101.61% |
| Average Diluted Shares Outstanding | 20.83% | 44.49% | 68.31% | 92.96% | 105.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |